Xenetic Biosciences
Update in progressXBIO (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Xenetic Biosciences is a biopharmaceutical company focused on immune-oncology. Its DNase technology targets neutrophil extracellular traps (NETs) that can promote cancer growth, metastasis, and resistance to therapies. The pipeline includes XBIO-015 for pancreatic and solid tumors, XBIO-020 for solid tumors, and ErepoXen using PolyXen for anemia in chronic kidney disease. Based in Framingham, MA, it has a Takeda sublicensing agreement and partnerships with Serum Institute of India, Pharmsynthez, and SynBio.
Company score
- Sentiment
- 0.11
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.12
- Governance
- -0.22
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.05
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. James F. Parslow
- Employees2
- Websitewww.xeneticbio.com
Identifiers
- ISINUS9840155033
- FIGIBBG0028WJXC0
- LEI5493002WV0KYX8JXAH52
- CUSIP984015107
- CIK0001534525